INmune Bio Inc. to Report Third Quarter 2026 Financial Results and Provide Corporate Update on Thursday, November 5th
Globe Newswire•29/10/2026•09:15 ET
0
Key Highlights
- ➤INmune Bio will report Q3 2026 financial results November 5 at 4:30 p.m. ET
- ➤CORDStrom MAA submissions planned for UK MHRA and EU EMA in 2026
- ➤INmune Bio plans U.S. BLA submission for CORDStrom
- ➤XPro1595 positioned for integrated Phase 2b/3 Alzheimer’s registrational program
Expert Statements
David Moss, Chief Executive Officer of INmune Bio
“INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.”
Management to host conference call and webcast at 4:30 pm ET on that day
BOCA RATON, Fla, Oct. 29, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced t that it will host a conference call on Thursday, November 5(th), 2026 at 4:30pm EDT to discuss results for its quarter ended September 30, 2026 and to provide a corporate update.
Get started
Create a free account to read the full story.